These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 19851511

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG.
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [Abstract] [Full Text] [Related]

  • 3. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
    Binkley N, Martens MG, Silverman SL, Derman RJ, Greenwald M, Kohles JD, Bachmann GA.
    South Med J; 2009 May; 102(5):486-92. PubMed ID: 19373149
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY.
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia.
    Vlak T, Kaštelan D, Lozo P, Aljinović J, Gradišer M, Mijić S, Nikolić T, Miškić B, Car D, Tajšić G, Dušek T, Jajić Z, Grubišić F, Poljičanin T, Bakula M, Džubur F, Strižak-Ujević M, Kadojić M, Radman M, Vugrinec M, Kuster Z, Pekez M, Radović E, Labar L, Crnčević-Orlić Z, Koršić M.
    Clin Rheumatol; 2011 Dec; 30(12):1549-54. PubMed ID: 21956235
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC, Bauss F.
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [Abstract] [Full Text] [Related]

  • 13. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
    Chung YS, Lim SK, Chung HY, Lee IK, Park IH, Kim GS, Min YK, Kang MI, Chung DJ, Kim YK, Choi WH, Shong MH, Park JH, Byun DW, Yoon HK, Shin CS, Lee YS, Kwon NH.
    Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ibandronate: a review of its use in the management of postmenopausal osteoporosis.
    Frampton JE, Perry CM.
    Drugs; 2008 Nov; 68(18):2683-707. PubMed ID: 19093707
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR.
    J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.
    Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P.
    Osteoporos Int; 2012 Jun; 23(6):1747-56. PubMed ID: 21953471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.